Generic Duetact Availability

Duetact is a brand name of glimepiride/pioglitazone, approved by the FDA in the following formulation(s):

DUETACT (glimepiride; pioglitazone hydrochloride - tablet;oral)

  • Manufacturer: TAKEDA PHARMS USA
    Approval date: July 28, 2006
    Strength(s): 2MG;30MG [RLD] [AB], 4MG;30MG [AB]

Has a generic version of Duetact been approved?

A generic version of Duetact has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Duetact and have been approved by the FDA:

PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE (glimepiride; pioglitazone hydrochloride tablet;oral)

  • Manufacturer: SANDOZ
    Approval date: January 4, 2013
    Strength(s): 2MG;30MG [AB], 4MG;30MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duetact. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical composition
    Patent 6,150,383
    Issued: November 21, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
  • Pharmaceutical composition
    Patent 6,211,205
    Issued: April 3, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
  • Pharmaceutical composition
    Patent 6,303,640
    Issued: October 16, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • August 9, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
  • Pharmaceutical composition
    Patent 6,329,404
    Issued: December 11, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
      ✓ 
      Drug product
  • Pharmaceutical composition
    Patent 7,538,125
    Issued: May 26, 2009
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Pharmaceutical Company Limited
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:
    • June 19, 2016
      ✓ 
      Drug product
  • Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
    Patent 7,700,128
    Issued: April 20, 2010
    Inventor(s): Doken; Kazuhiro & Kawano; Tetsuya & Koyama; Hiroyoshi & Hamaguchi; Naoru
    Assignee(s): Takeda Pharmaceutical Company Limited
    A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue, which comprises an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided.
    Patent expiration dates:
    • January 30, 2027
      ✓ 
      Drug product
  • Solid preparation
    Patent 8,071,130
    Issued: December 6, 2011
    Inventor(s): Kiyoshima; Kenichiro & Nakamura; Kenji & Kawano; Tetsuya & Misaki; Masafumi
    Assignee(s): Takeda Pharmaceutical Company Limited
    The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.
    Patent expiration dates:
    • June 8, 2028
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)